Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report

Shuang-xi Li; Rui-kang Hu; De-liang Kong; Jing Xu; Qi Bian; Zhi-Yong Guo; Xiao-bin Mei

doi:10.3389/fimmu.2025.1564242

Frontiers in Immunology (May 2025)

Efficacy of Telitacicept in treating IgA vasculitis nephritis: a two-case report

Shuang-xi Li,
Rui-kang Hu,
De-liang Kong,
Jing Xu,
Qi Bian,
Zhi-Yong Guo,
Xiao-bin Mei

Affiliations

Shuang-xi Li: Department of Nephrology, Changhai Hospital, The Naval Medical University, Shanghai, China
Rui-kang Hu: Medical School of Chinese People’s Liberation Army (PLA), Beijing, China
De-liang Kong: Department of Nephrology, Changhai Hospital, The Naval Medical University, Shanghai, China
Jing Xu: Department of Nephrology, Changhai Hospital, The Naval Medical University, Shanghai, China
Qi Bian: Department of Nephrology, Changhai Hospital, The Naval Medical University, Shanghai, China
Zhi-Yong Guo: Department of Nephrology, Changhai Hospital, The Naval Medical University, Shanghai, China
Xiao-bin Mei: Department of Nephrology, Changhai Hospital, The Naval Medical University, Shanghai, China

DOI: https://doi.org/10.3389/fimmu.2025.1564242
Journal volume & issue: Vol. 16

Abstract

Read online

Telitacicept, a B lymphocyte stimulator/A proliferation-inducing ligand dual-target fusion protein, mainly used for IgA nephropathy and systemic lupus erythematosus. We present two cases where adult patients with IgA vasculitis (IgAV) nephritis were successfully treated with Telitacicept, experienced no adverse reactions during the follow-up. Therefore, Telitacicept represents a promising additional treatment option for patients suffering from IgA vasculitis (IgAV).

Published in Frontiers in Immunology

ISSN: 1664-3224 (Online)
Publisher: Frontiers Media S.A.
Country of publisher: Switzerland
LCC subjects: Medicine: Internal medicine: Specialties of internal medicine: Immunologic diseases. Allergy
Website: http://journal.frontiersin.org/journal/immunology

About the journal

Abstract

Keywords